KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Average Rating of “Moderate Buy” by Analysts

KORU Medical Systems, Inc. (NASDAQ:KRMD) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.8750.

A number of equities analysts recently issued reports on KRMD shares. Lake Street Capital raised their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Wednesday, October 8th. Wall Street Zen downgraded KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 4th. Finally, Canaccord Genuity Group raised their price objective on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, December 17th.

Institutional Investors Weigh In On KORU Medical Systems

Several institutional investors and hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC lifted its position in KORU Medical Systems by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock valued at $16,760,000 after acquiring an additional 226,700 shares in the last quarter. Topline Capital Management LLC raised its stake in shares of KORU Medical Systems by 1.1% in the third quarter. Topline Capital Management LLC now owns 3,648,240 shares of the company’s stock worth $13,973,000 after purchasing an additional 39,893 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of KORU Medical Systems by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,145,772 shares of the company’s stock valued at $8,218,000 after purchasing an additional 60,109 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of KORU Medical Systems by 101.3% in the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after purchasing an additional 501,875 shares in the last quarter. Finally, Acuitas Investments LLC boosted its position in shares of KORU Medical Systems by 89.6% during the third quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock valued at $2,923,000 after buying an additional 360,594 shares during the last quarter. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Stock Performance

NASDAQ KRMD traded down $0.16 on Friday, reaching $5.65. The stock had a trading volume of 115,345 shares, compared to its average volume of 157,799. KORU Medical Systems has a 1-year low of $1.86 and a 1-year high of $6.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. The company has a market cap of $261.71 million, a P/E ratio of -70.63 and a beta of 0.51. The firm has a fifty day moving average of $5.30 and a two-hundred day moving average of $4.37.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.